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This dissertation aims at determining the fair value of Almirall SA equity. The pharmaceutical 
industries, as well as Almirall SA were researched in detail. Different theoretical approaches 
were discussed in a literature review that represents the “state of the art” in equity valuation. 
Based on the literature review, Almirall SA was valued with a sum of the part valuation, 
including a discounted cash flow valuation for the mature business, a discounted multiple 
valuation for the company research and development activity and a net present value 
valuation for income incurring from the recent transaction with AztraZeneca in 2014. The fair 
value of 16.2 Euros per share determined the target price of this valuation, based on 
comparing said price with the current share price of 18.4 Euros, I made a recommendation for 
investors to sell the stock. Finally, this dissertation’s recommendation and valuation was 
compared with another from an equity research report from Credit Suisse and I proceeded to 
explain the differences in the recommendation and valuation, which might arise from 
different assumptions, valuation methods and recommendation method used. 
Esta dissertação tem como objectivo determinar o valor justo da acção da Almirall SA. A 
indústria farmacêutica, bem como a Almirall SA foram analisados em detalhe. Abordagens 
teóricas diferentes foram discutidas numa revisão de literatura que discute os métodos mais 
sofisticados e actualizados de avaliação de empresas. Com base na revisão da literatura, a 
Almirall SA foi avaliada como uma soma das partes, incluindo uma avaliação fluxos de caixa 
descontados para o negócio maduro da empresa, uma avaliação de múltiplos descontada para 
a actividade da empresa em investigação e desenvolvimento e uma avaliação do valor 
presente líquido para a renda proveniente da transacção recente com a AztraZeneca em 2014. 
O valor justo de 16.2 Euros por acção determinou o preço-alvo desta avaliação, com base na 
comparação do referido preço com a preço actual de 18.4 Euros, fiz uma recomendação aos 
investidores para vender a acção. Finalmente, a recomendação e avaliação desta dissertação 
foram comparadas com outras de um relatório de análise do Credit Suisse e as diferenças que 
surgiram na recomendação e avaliação foram discutidas, tendo em conta os pressupostos, os 
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APV Adjusted Present Value 
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1 - INTRODUCTION 
This dissertation intends to determine a realistic approximation to the fair value of ALM SA 
and compare it with the current market price of 4 of January and make a recommendation to 
either buy sell or hold the stock.  
FIGURE 1: SHARE PRICE EVOLUTION 
 
ALM Stock price has increased substantially over the last years, due to the company 
strategy’s redirection and M&A activity. The purpose of this dissertation is to analyse if 
ALM’s current price of 18.4 correctly accesses its’ fair value. I based my analysis on 
fundamental research and perspectives for the short and long run for the pharmaceutical sector 
and the company. Furthermore, this dissertation establishes a market value to the R&D 
activity that ALM is undergoing. 
The key question this dissertation aims to answer is the following:  
Is the current market price correctly valuing ALM’s current business, R&D activities and the 
potential of the recent transactions? 







2 - REVIEW OF RELEVANT LITERATURE 
 
This section purpose is to present an overview of the state-of-the-art methods, which are 
usually used when performing a company firm valuation. 
Firm valuation is widely used in the finance realm, it is used to test market efficiency, to 
determine corporate strategy decisions and as a tool in investment and capital budgeting 
decisions. (Damodaran, 2002) 
In this literature review, I explained in detail different methods and the advantages and 
disadvantages associated with each of them, I focused on methods which may be used for 
ALM’s Valuation. 
As stated in All Roads Lead to Rome “we are fast approaching the point of valuation 
overload” (Holt, et al., 1999), in line with this citation, there is a need to clarify and explain 
the methodologies that are considered the most up to date and correct approaches of valuation 
available. The key theoretical assumption of firm valuation is that even though different 
methods are complex and use different data, the valuation result should be equivalent (Holt, et 
al., 1999). 
Damodaran argues there are four broad approaches to valuation (Damodaran, 2006). The first 
and most commonly accepted is the discounted cash-flow approach, it determines the fair 
value of an asset by considering the cash that it will generate throughout its life-time 
discounted to the present. A second method, the liquidation or accounting valuation, assesses 
the value of firms taken into account the book value of its assets. A third approach, relative 
valuation, which is a fairly popular method, relies on multiples and uses benchmarking based 
on an adequate group of peers. The fourth approach, contingent claim valuation, is performed 
when assets display option like characteristics and therefore are valued with option pricing 
(Damodaran, 2006). 
While Damodaran considers there are four broad approaches to valuation (Fernández, 2015), 
Fernández argues there are six. The two additional methods purposed by Fernández are the 
goodwill base method and value creation method. Goodwill accounts for the company’s 
intangible assets which usually are not reflected in the book value but can be an essential 
advantage in many industries, those hard to measure intangibles assets can be brands, 
strategic alliances, costumer portfolio, etc.  
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2.1 - COST OF CAPITAL 
 
2.1.1 - WEIGHTED AVERAGE COST OF CAPITAL 
 
The WACC method is suitable to value simple and stable capital structures and it is used to 
discount cash-flows that an asset will generate. The method consists in calculating a discount 
rate that accounts for the value created, or not, by the financing structure of the company. Due 
to this fact, the WACC commonly needs to be adjusted to include tax shields, subsidies, 
hedges, different types of debt securities, issue costs and changing capital structures 





× 𝐾𝑑 × (1 − 𝑇) +
𝐸
𝐷 + 𝐸
× 𝐾𝑒  
The WACC is expected to reflect the business risk adjusted to the capital structure, normally 
it is calculated by multiplying the after tax cost of debt and cost of equity by the respective 
weights in the capital structure. Other inputs may be included if applicable and different 
adjustments should be applied in case we are dealing with complex capital structures 
(Luehrman, 1997). To determine debt weight in the capital structure, generally it is assumed 
the company has a target capital structure (Damodaran, 2002). On other occasions when the 
debt level is expected to change, readjustments to the WACC are needed (Fernandéz, 1997).  
 
2.1.2 - COST OF EQUITY 
 
The cost of equity is the expected return on equity demanded by investors and it is calculated 
by adding a premium, which is the market risk premium adjusted for the company 
sensitiveness to the market risk, to the riskless rate (Damodaran, 2002). 
FORMULA II: 
𝐾𝑒 = 𝑅𝑓 + 𝛽 × 𝑀𝑘𝑝𝑟𝑒𝑚𝑖𝑢𝑚 
The Βeta is a measure of company risk, it includes systematic risk and risk deriving from the 
firm’s capital structure (Damodaran, 2002). 
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The cost of equity can be levered or unlevered, representing the overall risk of the firm or just 
the assets risk without the effect of leverage, respectively (Damodaran, 2002). 
 
2.1.3 - COST OF DEBT 
 
The cost of debt is the return expected by the firm’s debtholders and it is calculated by adding 
a spread on the risk-free rate based on the default risk (Damodaran, 2002).  
Rating agencies often rate public companies and determine a spread based on that rating that 
rating. Alternatively, the cost of debt can be calculated by the available yield to maturity if the 
company has publicly traded bonds or by a synthetic rating based on the interest coverage 
ratio of the company (Damodaran, 2002). 
FORMULA III: 
𝐾𝑑 = 𝑅𝑓 + 𝑠𝑝𝑟𝑒𝑎𝑑 
After we determine the pre-tax cost of debt we adjust for the tax benefits of debt. 
FORMULA IV: 
𝐴𝑓𝑡𝑒𝑟 − 𝑡𝑎𝑥 𝑐𝑜𝑠𝑡 𝑜𝑓 𝑑𝑒𝑏𝑡 = 𝐾𝑑 × (1 − 𝑇) 
The underlying assumption on the after-tax cost of debt is that interest is tax deductible, Thus 
increasing leverage will lower the amount paid in taxes and maximize the firm’s value up 
until a certain point, when bankruptcy costs and other adverse effects start to outweigh debt’s 
benefits (Damodaran, 2002). 
 
2.1.4 - TAX RATE 
 
When determining which tax rate to use in valuation, there are arguments in favour of using 
either the effective or the corporate marginal tax rate (Damodaran, 2002). Both figures usually 
show some discrepancies, mainly due to deferring taxes, use of different accounting standards 
for reporting and tax purposes and tax credits (Damodaran, 2002). Damodaran argues that 
because none of the reasons that explain the difference between effective and marginal tax 
rates are usually sustainable in the long run, effective tax rate should converge to corporate 
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marginal tax rate, and in the long run, marginal tax rate is the most robust assumption. Still, 
Damodaran suggests that when estimating cash flows, one can use the effective tax rate in the 
first years and use the marginal tax rate in subsequent years and terminal value (Damodaran, 
2002). 
 
2.1.5 - RISK FREE RATE 
 
To be considered risk free, an instrument has to be default free and its expected return has to 
equal to the actual return. Therefore the instrument used should be a zero coupon treasure 
bond with long term maturity that pays in the same currency as the investment (Damodaran, 
2002).  
The underlying reasons for the aforementioned choice of instrument are the fact that the 
central bank can issue currency and act as lender of last resort, assuring the default free nature 
of the security, the fact that the bond is zero coupon, which implies there is no reinvestment 
risk on which the coupon will be invested at different rates that result in actual return being 
different from the expected (Fernández, 2004; Damodaran, 2002), it complies with the 
consistency principle that states the instrument used as the risk-free rate has to return in the 
same currency as the project estimated cash flows, to assure there are no currency exchange 
discrepancies (Damodaran, 2002) and the long term maturity which mimics the life-time of 
the investment, a long term maturity is more accurate for a firm that is a going concern. 
(Damodaran, 2002). 
 
2.1.6 - MARKET RISK PREMIUM 
 
The market risk premium is the excess return of the market to the risk free rate. Traditionally, 
analysts use the historical average market risk premium when performing valuations, but 
there are divergent views regarding the time period that should be used when calculating the 
market risk premium. 
The historical risk premium boldly assumes that investor risk premiums and the average risk 
of investments have remained stable over time. Some academics argue that this assumption is 
incorrect and shorter more recent time periods should be used to calculate the average risk 
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premium. Although recent time periods seem more appropriate to measure market risk, 
academics argue that shorter periods of time exhibit higher errors (Damodaran, 2002; 
Damodaran, 2011; Fernández, 2004). Concluding, there is no consensus on which risk 
premium to use, the historical average or the average of a recent period. 
 
2.1.7 - COUNTRY SPECIFIC RISK 
 
When considering valuation of non-US companies, one has to take into account the country 
specific risk. Some consider country risk as diversifiable, that developed and emerging 
markets share similar risks (Goedhart & Haden, 2003) and historical Beta already includes 
country risk premium.  
Fernández lists those aforementioned arguments in the list of 80 common errors in company 
valuation (Fernández, 2004) and argues along with other academics that country risk is non-
diversifiable (Damodaran, 2002), implying that investors tend to be biased against different 
markets, therefore there is a country specific risk.  
A simply way to measure this country risk premium is to use the rating provided by agencies 
such as Moody’s and S&P and their respective default spread (James & Koller, 2000), this 
spread is added to the cost of equity (Damodaran, 2002; Damodaran, 2011). 
FORMULA V: 
𝐾𝑒 = 𝑅𝑓 + 𝛽 × 𝑀𝑘𝑅𝑖𝑠𝑘 𝑝𝑟𝑒𝑚𝑖𝑢𝑚 +  𝐶𝐷𝑆 
 
2.1.8 - ΒETA 
 
According to the CAPM, to determine the Beta of the company one must regress its stock 
return against the market return. The Beta will be the slope of the regression and it will 
represent the sensitiveness of the stock price to market variations (Fama & French, 2004). 
FORMULA VI: 








Formula VI regression allows us to obtain the raw βeta of a company. 
The Raw Beta tends to be an accurate risk measure when valuing a widely traded firm, but for 
private firms, public firms that have low trading volume, companies that have undergone 
leverage changes or acquired new business recently using the bottom-up Beta is a better 
approach (Damodaran, 2002).  
To determine the bottom-up Beta to use in valuation, we should gather an adequate peer 
group, composed of similar companies in terms of market capitalization, industry, size and 
geography (Damodaran, 2002). 
 We should calculate for each of those peers, the unlevered Beta. 
FORMULA VIII: 




Generally there is the assumption that 𝛽𝑑 = 0 and the formula is simplified as in formula IX. 
FORMULA IX: 




Fernández list the use of the formula IX in every cases as one of 80 common mistakes in 
valuation, suggesting the framework in formula if leverage is expected to increase. 
FORMULA X: 




The Beta of the company tends to approximate the market average of 1 in the long run. 
Damodaran suggest adjusting the Beta as in formula XI (Damodaran, 2002). 
FORMULA XI: 
𝐴𝑑𝑗𝑢𝑠𝑡𝑒𝑑 𝐵𝑒𝑡𝑎 = 𝑅𝑎𝑤 𝐵𝑒𝑡𝑎 × (0.67) + 1.00 × (0.33) 
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The unlevered Beta measures the business risk of the company. The unlevered Beta differs 
from the levered Beta due to only taking into account the systematic risk relative to the 
market, excluding the risk of financial leverage (Damodaran, 2002). Once the unlevered Beta 
of each peer is obtained, a simple or Mk Cap weighted average is calculated and that average 
will correspond to the unlevered beta of the company we aim to value (Damodaran, 2002). 
The unlevered Beta is then levered considering the capital structure of the company 
(Damodaran, 2002). 
 
2.2 - ECONOMIC VALUE ADDED 
 
EVA is the surplus value generated by an investment, in essence the excess return to the cost 
of capital deployed on an investment. 
FORMULA XII: 
𝐸𝑉𝐴 = (𝑅𝑂𝐼𝐶 − 𝐾) × 𝐼 
To calculate the EVA, there are three basic inputs, the capital invested, the return on invested 
capital and the cost of capital.   
The best estimate for invested capital should be the assets book value (Damodaran, 2002).  
While to estimate the ROIC we use the net operating profit less adjusted taxes (NOPLAT) 
over the invested capital, the cost of capital should be the average cost of capital according to 






According to Damodaran, to estimate the NOPLAT, tax adjustments should be subtracted to 
the operating profit or EBIT (Damodaran, 2002), additionally, the operating profit should be 
adjusted for operating leases, R&D expenses and non-recurrent events.  
To determine the EV using the EVA approach one has to sum the value added each year 











2.3 - DISCOUNTED CASH FLOW 
 
The DCF approaches are widely used and considered the most theoretically sound. The 
underlying logic behind DCF is that the fair value of a firm is the cash that the firm is able to 
generate throughout its life-time discounted to the present at an adequate rate that reflects the 
risk of the firm’s cash-flows. (Damodaran, 2006). 
The DCF approach uses the financial statements as its base and forecasts the income and 
cash-flow statement in order to calculate the future cash-flows of the firm (Luehrman, 1997).    
When performing valuation in some R&D intensive industries, like the pharmaceutical 
industry, immediately expensing R&D might have a distortionary effect on earnings and cash-
flows, which can be adjusted by capitalizing R&D expenses. The amortizable life of the R&D 
investment is the number of years it takes for the research subject to become a product 
(Damodaran, 2002; Keegan, 2008). If the EBIT is adjusted in this fashion, the distortion that 
heavy R&D effects create on operating income in a given year is mitigated between the years 
of the investment amortizable life. 
 
2.3.1 - FREE CASH FLOW TO THE FIRM 
 
The free-cash-flow to the firm or FCFF values the EV as whole. FCFF excludes cash-flow 
deriving from financing activities of the company such as interest or dividends (Damodaran, 
2002) and focus only on cash generated by operations. The capital structure is then reflected 
in the discount rate, the WACC. 
FORMULA XV: 
𝐹𝐶𝐹𝐹 = 𝑁𝑂𝑃𝐿𝐴𝑇 − 𝛥𝑁𝑊𝐶 − 𝐶𝐴𝑃𝐸𝑋 + 𝐷𝑒𝑝 & 𝐴𝑚𝑜𝑟𝑡 
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To obtain the FCF, one should adjust the operating income for taxes obtaining the NOPLAT, 
additionally, depreciation and amortization is added because it is non-cash expense, net 
working capital increases which account for cash tied up in working capital are subtracted 
along with capital expenses (Damodaran, 2002). 
The EV is the sum of free cash-flows generated from the operating and investing activities for 








After determining the EV, one should make further adjustments to obtain the market value of 
equity. Minority interest and net debt should be subtracted to the EV (Damodaran, 2002). 
FORMULA XVII: 
 𝐸𝑛𝑡𝑒𝑟𝑝𝑟𝑖𝑠𝑒 𝑉𝑎𝑙𝑢𝑒 = 𝑀𝑘 𝐶𝑎𝑝 + 𝐷𝑒𝑏𝑡 − 𝐸𝑥 𝑐𝑎𝑠ℎ + 𝑀𝑖𝑛  𝐼𝑛𝑡𝑒𝑟𝑒𝑠𝑡 + 𝑃𝑟𝑒𝑓 𝑆ℎ𝑎𝑟𝑒𝑠 
Once the market value of equity is calculated, it should be divided by the number of shares 
outstanding to obtain the fair value per share, the theoretical share price. 
 
2.4.2 - ADJUSTED PRESENT VALUE 
 
Although the FCFF method is a theoretical sound approach, some academics consider the 
APV a better method (Luehrman, 1997). Luehrman argues that analysts should use APV 
instead of the FCFF due to the fact that APV is always applicable when the FCFF is, it 
requires less strict assumptions, it is subject to less errors and is more complete as a valuation 
tool as it shows where the value of the company is created, either from the firms operations or 
from financial engineering. 
Unlike the FCFF method that forecasts cash-flows and discounts them at the WACC, APV 
values the financial structure advantages or disadvantages separately and then adds them to 




𝐴𝑃𝑉 = 𝑉𝑢 + 𝑉𝑇𝑆 − 𝐵𝑢𝑛𝑘𝑟𝑢𝑝𝑐𝑦 𝑐𝑜𝑠𝑡𝑠 + ℎ𝑒𝑑𝑔𝑒𝑠 + 𝑠𝑢𝑏𝑠𝑖𝑑𝑖𝑒𝑠 − 𝑖𝑠𝑠𝑢𝑒 𝑐𝑜𝑠𝑡𝑠 − 𝑜𝑡ℎ𝑒𝑟 𝑐𝑜𝑠𝑡𝑠 
The APV uses the unlevered cost of equity as the discount rate and it is especially useful 
when the firm´s financial leverage is expected to change over time because the discount rate 













According to Fernández, to determine the terminal value for companies that maintain a 
constant book value leverage ratio, the terminal value of tax Shields should be calculated 
using formula XX (Fernández, 2007) 
FORMULA XX: 
𝑉𝑇𝑆 =
𝐷 × 𝐾𝑢 × 𝑇
𝐾𝑢 − 𝑔
 
For alternative financing strategies such as keeping a constant market value of debt ratio, on 
which the company’s debt grows with the market value of equity, one should use the Miles-
Ezzel formulation present in formula XXI, which assumes that the appropriate discount rate 












2.4.3 - TERMINAL VALUE 
 
When the firm is a going concern, one has to determine the terminal value of the company 
after an explicit period of cash-flow estimation. There are three ways of calculating the TV, 
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assuming that the TV is the book value of the company’s assets if liquidated at the end of the 
explicit period, applying a multiple in the terminal year or assuming that cash flows grow at a 






In the terminal year at a stable growth rate, capital expenditures should offset depreciations, 
essentially the company reinvests to replace existing assets. Furthermore, the estimated 
terminal growth rate has to be a reasonable figure relative to the nominal growth rate of the 
economy where the firm operates, as a rule of thumb, it shouldn’t exceed the GDP growth rate 
by more than 2% (Damodaran, 2002). Additionally firms with excess returns can´t maintain 
them forever, therefore in the long run excess returns should equal the cost of capital. 
 
2.5 - EQUITY CASH-FLOW METHODS 
 
2.5.1 - DIVIDEND DISCOUNT MODEL 
 
The DDM is an equity valuation model that is based on valuing the firm’s equity as the 
dividend per share paid to shareholders during the firm’s lifespan (Farrell, Jr., 2010). Farrell 
Jr. argues that analogous to the price of a bond, the price of a stock should be the stream of 
dividend payments entitled to the shareholders during the life-time of the company. The DDM 
model assumes the company is a going concern and dividends are discounted at a cost of 
equity, the required rate of return for equity investors (Damodaran, 2002), additionally there 
is a dividend growth rate, which is expected to keep constant and grow at the same rate as the 
other key performance metrics. Formula XIII is generally referred to as Gordon’s growth 
model. 
FORMULA XXIII: 




There are two basic inputs in the model, the expected dividend per share and the ke. To obtain 
the expected dividend per share, one must make projections and assumptions on the company 
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earnings and pay-out-ratio (Damodaran, 2002). The cost of equity is the required rate of 
return required by shareholders, which is essentially the compensation that investors require 
for forgoing saving or consuming, it is composed by the risk free rate and a market risk 
premium that includes interest rate risk, purchasing power risk, business risk and financial 
risk (Farrell, Jr., 2010). 
 
2.5.2 - FREE CASH-FLOW TO EQUITY 
 
The FCFE is an equity valuation model and a derivation of the DDM, it assumes the cash-
flow left after the firm faces its financial obligations is paid as dividends and the expected 
growth rate includes only the increase in income from operating assets and not income 
streaming from marketable securities and other financial results (Damodaran, 2006). 
Compared to FCFF, FCFE uses the net income as its base instead of NOPLAT. Interest 
related expenses are relevant because debt holders have seniority claims compared to 
shareholders (Damodaran, 2002). FCFE accounts for the cash-flows that are left after 
investing into net working capital needs, CAPEX, facing all financial obligations and 
borrowing and re-paying principal payments on debt. (Damodaran, 2002). 
FORMULA XXIV: 
𝐹𝐶𝐹𝐸 = 𝑁𝑒𝑡 𝐼𝑛𝑐𝑜𝑚𝑒 − 𝐶𝑎𝑝𝑒𝑥 + 𝐷𝑒𝑝 & 𝐴𝑚𝑜𝑟𝑡 − 𝛥𝑁𝑊𝐶 + 𝑁𝑒𝑡 𝐵𝑜𝑟𝑟𝑜𝑤𝑖𝑛𝑔 
FCFE models value the equity stake of the business as the perpetual cash flows entitled to the 
shareholders discounted at the levered cost of equity (Damodaran, 2006). 
 
 
2.6 - VALUATION OF PHARMACEUTICAL COMPANIES 
 
Due to the nature of pharmaceutical companies’ business models, which imply an initial cash 
burn for a promise of future revenue streams from successfully developed drugs, performing 
firm valuation can prove a challenging task where traditional DCF approaches might not be 




2.6.1 - THE NPV OF R&D PIPELINE 
 
To value a portfolio of R&D projects currently under development and that are subject to 
approval by legal entities, analysts and experts tend to adjust the NPV by attributing 
cumulative probabilities of success according to the phase of R&D development that the drug 
is in (Keegan, 2008). 
Keegan argues that in order to estimate probabilities of a developing drug making it 
successfully to market, one has to know the R&D process in drug development, (Keegan, 
2008). A process that encompasses two broader phases, drug discover and research and the 
regulatory process. 
Drug discovery and research starts with the pre-clinical stage where the drug is tested in 
animals. The pre-clinical stage is considerably cheaper than latter stages and the chances of a 
developing drug reaching the market at this stage is less than 10% (Keegan, 2008). After the 
pre-clinical phase, there are four stages of clinical trials. Stage I accesses drug safety, the 
probability of successfully progressing to the next stage is 70%, it may last several months 
and it accounts for approximately 10% of R&D spending (Keegan, 2008). Stage II tests the 
dose range and efficiency of the drug and it is considered the proof of concept stage, it may 
last up two years, around 50% of drug candidates in this phase pass to stage III and it 
averages 25% of total R&D spending. Stage III is the last stage before the drug is launched to 
market and therefore tests the efficacy relative to other treatments or placebos in large scale 
trials, it accounts for 35% of R&D expenses, the probability of successfully passing stage III 
is 60% and it may last from 2 to 5 years. Phase IV occurs after the product is already in the 
market and it acts as a surveillance test (Keegan, 2008). 
After the first three research trials are complete, the drug is subjected to regulatory approval, 
the regulators will weigh the benefits and risks of the drug candidate. Around 90% of 
proposed drugs are approved by regulators.  
As mentioned previously, conventional valuation methods are not the most reliable when 
dealing with pharmaceutical companies, especially in what concerns the value of its 
intangible assets, the drugs under development which are generally called the R&D pipeline.  
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The best estimation possible to compute the NPV of a pipeline is to do a sum of the parts 
valuation by adding the different projects NPV’s to obtain the R&D pipeline value (Keegan, 
2008).  
To calculate the probability weighted NPV of an R&D project, aside from a probability, 
Keegan suggests we must estimate peak sales some years after the drug is launched in the 
market and an associated profitability rate to estimate peak earnings, revenue increments 
could either be by direct sales or royalty payments (Keegan, 2008). Once peak earnings are 
estimated, a multiple should be applied to the success probability weighted estimated peak 
earnings and that value should be discounted to the current year. Adding the NPVs of the 
different development assets results in the probability weighted NPV of the total R&D 
portfolio.  
FORMULA  XXV: 







The success probability is a cumulative success probability, based on the probability of 
successfully passing the successive stages. If we can successfully identify the cost in each 
stage, it is possible to build a decision tree a decision tree based model with the NPV at each 
decision node (Keegan, 2008). 
In order to estimate the market size for a potential drug, we should build a market model 
based on the incidence of the disease treated, treatable population, market penetration and 
annual cost per patient (Keegan, 2008). 
FORMULA XXVI: 
𝐴𝑑𝑟𝑒𝑠𝑠 𝑀𝑘 𝑆𝑖𝑧𝑒 =  𝑇𝑟𝑒𝑎𝑡 𝑃𝑜𝑝 × 𝐸𝑠𝑡𝑖𝑚 𝑀𝑘 𝑃𝑒𝑛𝑒𝑡𝑟𝑎𝑡𝑖𝑜𝑛 ×  𝐶𝑜𝑠𝑡 𝑝𝑒𝑟 𝑃𝑎𝑡𝑖𝑒𝑛𝑡 
There are some aspects to have in mind when valuing a product pipeline, for instance, when 
calculating the incidence or prevalence of a disease one should rely on scientific 
epidemiological data, additionally to accurately estimate the cost of drug per patient one 
should compare with similar drug prices on the market.  
Official entities provide estimate for US and European drug prices, drugs in Europe tend to 
sell at a discount compared to the US. Once a price is established, one must know the 
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theoretical number of doses per treatment or treatment period, thereafter it is possible to 
estimate the annual cost per patient.  
Once we obtain a Market size figure we should analyse global sales forecasts by research 
entities to reality check our own estimates (Keegan, 2008). 
 
2.6.2 - OPTION VALUATION 
 
In investment analysis, the decision to undertake a project depends on the project having a 
positive NPV. This traditional approach to finance is somewhat limited when its valuing 
projects that have an option like nature, mainly the option to delay the project (Damodaran, 
2002).  
The underlying reason for delaying a project is the CF’s volatility, an investment with a 
current negative NPV might have a positive NPV in the future. Real option valuation assumes 
a time premium that can exceed the value of cash-flows of the following periods even after 
the NPV is positive, thus making it viable to delay the project to obtain higher valuations 
(Damodaran, 2002). Existence of exclusive rights to the project is a key assumption real 
option valuation. 
According to Damodaran, there are three general cases where a real option valuation method 
is applicable, which are natural resources firms that have undeveloped reserves and can chose 
to explore them at any time, normally when the natural resource price is higher, real estate 
firms that own undeveloped land and may choose to develop it when appropriate and 
companies that own patented products with exclusivity legal rights (Damodaran, 2002).  
A call option on an underlying asset is the possibility of buying a certain asset at a strike price 
for a certain period of time. To value a call option, the methods used are the binomial model 
and Black-Scholes model. The binomial model values American options which feature an 
early exercise possibility, at each node of the binomial tree the option can be exercised. 
The Black-Scholes model has stricter assumptions regarding options exercise, it considers all 
options are European and can only be exercised at maturity (Hull, 2012). Real Options are 




The Inputs used while performing an option valuation are the underlying asset, the strike 
price, the maturity, the variance and the riskless rate.  
The underlying asset in a security call option is the security itself, while in real option, it is the 
PV of the CFs streaming from the project (Hull, 2012; Damodaran, 2002). 
The strike price in the case of a call option is the pre-agreed contractual price on which we 
can buy the security (Hull, 2012), in the case of real option valuation, it will be the initial 
investment to start the project (Damodaran, 2002).  
The variance on a call option represents the expected movements in the price of the security 
(Hull, 2012), in real options the variance in the value of the project relates to the uncertainty 
involved in present value of the cash-flows that the project generates, it generally can be 
computed in one of three ways: one may use the variance of past similar projects that the 
company invested in, estimate probability for various market scenarios and compute the 
present value under each of the scenarios calculating the variance across those present values 
or use the variance in the value of firms in the sector as the estimate of variance in value of 
the project (Damodaran, 2002). The variance is the input, which has the most influence in the 
option’s value (Hull, 2012).  
The lifetime of call option is the time until the option expires, in real options that is the 
number of years the company has until the exclusive rights expire (Damodaran, 2002).  
The 𝑅𝑓 should be the zero-coupon Treasury bond rate with a maturity corresponding to the 
expiration date of the option (Damodaran, 2002). 
Although real option valuation is a theoretical sound approach, it is hard to apply in most 
practical cases. Among some of the limitations, keegan mentions that corporate investments 
are complex, lognormal distributed project values are hard to apply, hard to understand option 
valuation models and the difficulty of measuring the volatility of the market (Keegan, 2008). 
 
3 - RELATIVE VALUATION 
 
Relative valuation is usually achieved by benchmarking through the use of multiples, which 
are widely used and relied upon by analysts and financial institutions alike (Henschke & 
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Homburg, 2009). Multiples can be of various sorts, earnings, revenue, book value and even 
industry-specific multiples.  
According to Damodaran, there are three basic steps in relative valuation (Damodaran, 2002). 
The first is to find comparable assets priced by the market, analysts tend to choose companies 
in the same sector as comparable. The second step is to scale the market prices to a common 
variable to standardize prices and make them comparable, in firm valuation this is done by 
calculating the market value of equity or EV by multiples of earnings, book value or revenue. 
The last step is to adjust for the differences across the assets, their intrinsic characteristics, 
this requires understanding of how fundamentals influence the multiples values (Damodaran, 
2006). The standardization of the values of similar firms is done by making them relative to a 
common variable, such variables are earnings, EBITDA or sales, thus common multiples used 
in valuation are P/E or EV/EBITDA.  
Academic literature focus on the importance of using forward looking multiples instead of 
trailing multiples, using forecasts rather than historical data is a more accurate estimate and 
value predictor (Damodaran, 2006; Goedhart & Haden, 2003; Henschke & Homburg, 2009). 
Some multiples can be more adequate than others, for instance, while book value multiples 
such as PBV differ greatly across industries, EV/EBITDA multiples are more widely 
applicable. The EV/EBITDA multiple has a critical advantage; it excludes the distorting 
effect of financing structure in the analyses (Damodaran, 2002; Goedhart & Haden, 2003). 
Sector-specific multiples are useful for sectors that are hard to value by conventional 
multiples but they carry some disadvantages, those multiples tend to undervalue or overvalue 
companies and are harder to relate to fundamental analysis. (Damodaran, 2006). In some 
sectors such as biotechnology and pharmaceuticals, heavy R&D expenditure only generate 
increments in revenues and earnings in future years, thus a company can incur losses early on, 
on these cases, appropriate metrics to use as multiples inputs are the amount spent in R&D 
and number of employees working for the company (Keegan, 2008) 
When performing relative valuation on a company, the multiple used is an average of a group 
of adequate peers, operating in the same industries, with similar size, similar ROIC and 
growth rates (Goedhart, Koller and wessels, 2005). High growth and higher ROIC companies 
tend to have higher earning and price to book value multiples (Damodaran, 2006; Schreiner & 
Spremann, 2007).  
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Relative Valuation alongside DCF are the mainstream approaches to valuation nowadays 
(Henschke & Homburg, 2009; Damodaran, 2006), although both have significant different 
implications. DCF establish the fair value as the cash the assets will generate throughout its’ 
lifetime, while when using multiples one free-rides on market information assuming that the 
value of the company is what the market is willing to pay at the time, which can over or 
undervalue a company according to market momentum, figure 2 presents advantages and 
disadvantages of relative valuation.  
FIGURE 2: ADVANTAGES AND DISADVANTAGES OF RELATIVE VALUATION 
Advantadges Disadvantadges 
 Simple to use.  Comparability is subjective. 
 Useful when there are large 
numbers of comparable firms. 
 Mirrors market errors such as 
under or overvaluation. 
 Easy to understand.  Lack of fundamental analyisis. 
 Useful to reality check other 
valuation methods. 
 Lack of firm specific factors. 
 Widely used 
 Hard to find suitable peers. 
 Susceptibility to analyst bias. 
 
An important aspect of relative valuation is the existence of outliers, firms that trade at 
exceptional high or low values due to many possible reasons. Outliers in a group of peers can 
distort the value of the multiple if calculated by an average, In these cases, the peer group 
median is a more appropriate measure of the multiple to use in valuation (Damodaran, 2002). 
4 - COMPANY AND INDUSTRY OVERVIEW 
 
4.1 - ALMIRALL’S HISTORY 
 
ALM is a specialty pharmaceutical company located in Barcelona, Spain. The company was 
founded in 1943 and has been a pioneer in Spain’s pharmaceutical industry ever since, ALM 
has started its own research and development process in the 60’s and by 1987 it reached the 
status of market leader in Spain. The company has expanded its physical presence to other 
countries gradually, through acquisitions or creation of affiliates. Throughout its history ALM 
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has made substantial investment in chemical plants and research and development centers. In 
2007, ALM becomes listed in the IBEX and the company has launched blockbuster products 
such as Eklira®, an inhaler for COPD.  
Since 2013, the firm has become an active player in acquisitions mainly dermatology related 
and has disposed the respiratory franchise in a transaction with AZN.  
Currently ALM’s products are available in more than 70 countries and the company has a 
physical presence in 14. Most of its sales are in European markets mainly in Spain, its 
domestic market, even tough, recently ALM has focused its efforts in establishing a stronger 
presence in the US.  
 
4.2 - SWOT ANALYSIS OPERATING METRICS, BUSINESS AND GEOGRAPHIC 
PRESENCE 
 
Figure 3 presents a SWOT analysis, identifying the main strengths, weakness, opportunities 
and threats ALM is facing. The SWOT is mainly related with the focus on dermatology, the 
acquisition based strategy, the transaction with AZN and the strong financial position of the 
company. 
FIGURE 3: SWOT ANALYSIS 
 
As seen in figure 5, Europe and Spain account for roughly than 67% of total revenues, while 
North America represents roughly 25%, a figure that has increased recently driven by ALM’s 
strategic goal of becoming a key dermatology player in the US. For values table see Appendix 
XIX. 
Strengths Weakness
Focus on Dermatology Mature products declining
Financial situation Limited opportunities in R&D pipeline
Strong R&D track record Recent Acquistions risk
Opportunities Threats
Upcoming M&A activity Price pressure in the US
Synergies from concluded deals Dependence of AstraZeneca in common projects
Geographical expansion Patent Cliff and regulation changes
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FIGURE 4:SALES BY THERAPEUTIC AREA IN 2015 
 
ALM’s product Portfolio is focused on dermatology, which accounts for 43% of Sales in 
2015, in line with the company overall strategy of becoming a dermatology player. 
Respiratory agents once the main therapeutic area, now accounts for only 15% of the 
company sales, declining 50% from previous years due to recent divestment. Gastro and 
metabolism accounts for around 16% of sales in 2015, although its weight has been declining 
steadily it is still an important therapeutic area for the company strategy. For values table see 
Appendix XIII.  
 
FIGURE 5: SALES BY GEOGRAPHY IN 2015 
 
Figure 6 displays some key rations and metrics. The years 2013 and 2014 have been affected 
by the recent transactions.  
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FIGURE 6: RATIOS AND KEY METRICS 
 
The EBIT margin and net margin were exceptionally high due to other income relative to the 
transaction with AZN. Alternatively, net margins were negative in 2013 due to the acquisition 
of Aqua pharmaceuticals, which resulted in high restructuring costs.  
Gross margin is calculated over sales, while operating and net margin over total revenue 
which includes other income from royalties, joint development and marketing agreements and 
from previous transactions. 
FIGURE 7: REVENUE BREAKDOWN BY THERAPEUTIC AREA 
 
The change in focus to dermatology is visible in figure 7, ALM has increased its dermatology 
sales gaining a foothold in the US market, the US dermatology accounted for 22% of the 
company sales in 2015, and alternatively Europe Dermatology has experienced a slower 
growth and represents 21% of total sales.  Gastro and Metabolism and respiratory sales have 
similar weights in the company sales in 2015 and both have been decreasing its weight in total 
sales in the previous years, respiratory products decreased more abruptly in 2015, roughly 
Year 2011 2012 2013 2014 2015
Gross margin 62% 62% 66% 70% 69%
EBITDA margin 21% 18% 12% 87% 30%
EBIT margin 13% 8% 2% 77% 19%
Pre-tax margin 9% 7% -13% 61% 25%
Net margin 11% 11% -5% 57% 19%
Gen. & admin cost/Sales 36% 52% 55% 48% 41%
R&D/Sales 19% 23% 18% 13% 10%
Capex/(PPE+Intangibles) 8% 16% 41% 16% 13%
Net Debt/EBITDA 40% 28% 287% -54% -235%
Net Debt/Total Assets 4% 3% 14% -14% -19%
ROIC 11% 8% 0% 26% 4%
ROE 9% -4% 40% 9%
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50%, due to the transaction with AZN, which involved the sale of ALM’s once top seller 
Eklira® franchise.  
Other less important therapeutic areas include cardiology, which in 2011 accounted for more 
than 100 million Euros in sales, central nervous system including Sativex® franchise, 
musculoskeletal and urology. The weight of these other sales has been declining at an average 
of 15% per year and the trend is expected to continue. For values table see Appendix XIII. 
FIGURE 8: COST STRUCTURE  (% SALES) 
 
According to figure 8, the total cost structure over total sales, excluding other revenue from 
transactions and royalties, has been decreasing in the latter years, which implies the company 
has improved its operating efficiency. R&D, general and administrative costs and COGS have 
been decreasing steadily since 2012, thus margins have improved. This trend is expected to 
continue supported by the growth in dermatology, mainly in the US, which has better margins 
that the rest of the business.  
R&D and SGA’s over sales were 10% and 41%, respectively, in 2015. COGS have decreased 
as well from 38% in 2012 to 31% in 2015. For values table see Appendix XIV. 
 
4.3 - STRATEGIC GOALS 
 
ALM is recently turning around its focus within the pharmaceutical realm. Once, respiratory 
products accounted for most of firm’s sales, but recently the company strategy changed 
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completely with the acquisition of Aqua Pharmaceutical, a dermatology company in the US. 
With this deal ALM is on track to become a major player in dermatology in the US and aims 
at reinforcing its’ position on the European market as well. Additionaly, the company has 
made recent investments in aesthetics and management believes it will represent a significant 
part of the company sales in the near future. In Short ALM is optimizing its’ portfolio while 
making selective divestments. 
ALM’s key objetives include business and organization realignment through focus on 
dermatology and aesthetics fuelled by inovation and geographic expansion, acquisitions and 
R&D pipeline expansion are expected to be the catalyst for the near future,  
The company’s strategic goals started to be designed in 2014, when ALM announced the sale 
of part of its respiratory portfolio to AZN including the Eklira® franchise, the company top 
seller. The deal can ascend to roughly 2.1 Billion USD, 875 on completion of the deal and 
1.22 billion on milestones to be achieved.  
With the income generated from the sale ALM is determined to focus on dermatology 
acquisitions in order expand its product and R&D pipeline. Further disposals of non-core 
business units are expected as well and the company intends to spend anywhere between 500 
and 700 million Euros in acquisitions in the near future and the divestment in constella one of 




FIGURE 9: DERMATOLOGY AND RESPIRATORY REVENUES, 2012-2015 
 
In line with figure 9, In 2015, ALM increased its sales in dermatology, fueled by its’ US 
subsidiary.  
Recent catalysts for dermatology growth are the acquisition of Poli Group in November 2015, 
the product Swap in GSK and the acquisition of ThermiGen in February 2016. 
Poli Group is a Italian niche pharmaceutical company that generated 85 million in revenue in 
2015, 60% of the group sales are on dermatology, 20% are respiratory and 20% on 
gynecology, Poli Group was purchased for 400 Million Euros, 365 up front and 35 related to 
milestones.  
The GSK deal involved the acquisition of two products, Altabax® and Veltin®, in exchange 
for the rights for Toctino® and an undisclosed cash payment. Altabax® and Veltin® target 
impetigo and acne, further reinforcing Almiral’s Dermatology portfolio. 
ThermiGen LLC is an US based company, that develops temperature controlled radio 
frequency products that allows physicians to treat a variety of nerve and soft tissue conditions, 
the company generated 30 million in revenue in 2015.  
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FIGURE 10: TOP PRODUCTS BY REVENUE IN 2015 
 
Figure 10 presents an overview of ALM’s top 10 sellers and their growth rates in 2015.  
Aqua pharmaceuticals, ALM US subsidiary, is at the core of company strategy, its top 2 
sellers, the oral acne franchise Acticlate® and the Anti-inflammatory for dermatosis 
Cordran® are among the companies top 10 sellers, Showing ALM’s commitment to its’ 
redefined strategy. Furthermore, US dermatology portfolio will be reinforced by Altabax® 
and Veltin®. 
The mature business of ALM in other therapeutic areas is expected to decline further in the 
future, products like Almogran® and Ebastel®, whose patents have expired are expected to 
see further decreases in sales. 
Additionally, ALM’s is solely focused on developing dermatology related R&D projects in its 
pipeline, keeping respiratory projects aside with AZN, which are a part of the deal involving 
the 2 companies. R&D investment has been restructured and the company aims at keeping 








Area Patent Expiration Date
Monodox®/Acticlate® (doxycycline hyclate) 97 14% 43% yes Dermatology >2030
Ebastel® and other (ebastine) 62 9% -12% yes Respiratory Expired or Expiring 
Tesavel® & Efficib® (sitagliptine) 44 6% 0% no Endocrinology Exclusive Rights in Spain
Solaraze® (diclofenac sodium) 40 6% 6% no Dermatology >2020, licensed to Almirall
Airtal® and other (aceclofenac) 28 4% -1% yes Musculoskeletal Expired
Cordran® (flurandrenolide) 28 4% 17% yes Dermatology Undisclosed
Almax® (almagate) 24 3% 12% yes Gastroenterology Undisclosed
Decoderm® and others (flupredniden) 23 3% 6% yes Dermatology Undisclosed
Almogran® and other (Almotriptan) 18 3% -30% yes Neurology Expired or Expiring 
Balneum® (urea oil) 17 3% -1% yes Dermatology Undisclosed
Other Products 322 47%
TO P10 363 53%
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FIGURE 11: R&D PIPELINE 
 
 
4.4 - INDUSTRY OVERVIEW 
 
The pharmaceutical industry is one of major industry in the world, it is worth approximately a 
trillion USD and it is on verge of major changes.  
Technology progress will make way for the development of better treatments and new 
therapies for diseases previously untreated, population ageing and increase in age related 
disease incidence in advanced economies will be a major catalyst as well on the other side 
there are challenges facing pharmaceutical companies, the control of drug prices and the 
patent cliffs which a lot of firms are facing.  
The pharmaceutical industry, as whole, is expected to be driven by the economic recovery 
underway in developed markets along with the high growth in emerging markets, 
“pharmerging markets”. The higher innovation combined with the ageing of the population 
will foster the development of new therapies and treatments that improve the prognostics of 
numerous health condition. Diseases with once poor prognosis are turning chronic and 
specialty pharmaceutical are expected to be a driver behind future growth in the sector.  
In developed markets the trend of price cuts is expected to continue and especially in the US, 
where price restrictions on drugs may be applied after the outcome of the current 2016 
elections which might result in diminishing earnings for pharmaceuticals in the future. 
Project Goal Pre-clinical Phase I II III Expected Launch
Actikerall Actinic keratosis 2018
LAS41008 Plaque Psoriasis 2017
ADP31415 Pemphigus vulgaris >2021
LAS41006 Nail psoriasis 2021
AQ401 Acne >2021
LAS41010 Atopic Dermatitis 2017
Abediterol ICS Asthma & COPD 2021
LAS190792 COPD >2021
ADP31417 Asthma & COPD >2021
ADP71296 Asthma & COPD >2021
P-3058 Nail psoriasis 2020
P-3073 Onychomycosis 2020
P-3074 Male androgenic alopecia 2020
Projects directed by AstraZeneca
Projects w ith AstraZeneca
Acquired from Poli Group
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While the US market is expect to recoup and be the driver behind the pharmaceutical growth 
in the future, some European countries are undergoing budgetary constraints like Spain, 
Portugal or Greece, in those countries healthcare spending is expected to decrease in the near 
future.  
Additionally, the pharmaceutical industry was recently affected the by a large patent cliff, 
peaking in 2012, pharmaceutical companies saw their revenues plunge as their blockbuster 
compounds lose their exclusive rights and similar generic drugs flood the market at low 
prices, this trend seems to have waned in the latter years. 
The increase in generics and specialty pharma has contributed to a less consolidated market. 
The major companies have seen their combined market share decrease steadily making room 
for smaller companies focused on more specific target markets. 
In 2015, pharmaceutical turnover accounted for over a trillion in sales and is expected to keep 
growing at a steady pace.  
FIGURE 12: PHARMACEUTICAL INDUSTRY ANNUAL TURNOVER 
 
According to Statista, the Pharmaceutical Industry is expect to reach 1,4 Trillion USD by 
2020, growing at approximately 7% per year.  
Since intangibles are a company’s greatest asset, firms create patents on developing 
compounds to assure the future of its’ product pipeline and revenue stream in an ever-
changing competing environment. The industry is marked by recent M&A activity and heavy 
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R&D expenses as companies either acquire new business to avoid expending in drug 
development by acquiring new R&D pipeline or spend large amounts on R&D development. 
FIGURE 13: DERMATOLOGY INDUSTRY ANNUAL TURNOVER 
 
According to GBI Research, The global dermatology market was worth around 20 Billion 
USD in 2015. 
Global sales are expected to reach $33.7 billion in 2022, revealing an extraordinary potential 
in entering this therapeutic area with an implied estimated CAGR of 8%. 
Traditionally a therapeutic area with slow growth within the pharmaceutical realm, 
dermatology faces renewed growth fueled by innovative treatments for skin diseases, greater 
aesthetic awareness and increasing incidence of skin conditions. At the core of this growth is 
the dermatology devices market growing at 11% CAGR (Markets and Markets).  
The dermatology industry seems to be changing, as companies are extending indications of 
existing products in other therapeutic areas into dermatology. According to Skin Disease 
Treatment Technologies and Global Markets, the dermatology market divides into dermatitis 
(allergies and contact diseases), cancers (melanomas and other), immune disorders (psoriasis) 
and infections (bacterial, fungal and viral). The dermatology landscape has been marked by 
acquisitions, small and medium sized companies are being acquired by larger ones. According 
to Markets and Markets medical aesthetic market will be worth $12,5 billion in 2020, 
growing at 10,8% CAGR. 
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With the current shift in focus on dermatology and entering in the aesthetics market, ALM is 
facing stiff competition by the likes of Allergan, Valeant Pharmaceuticals, Zeltiq and 
Cynosure. valeant’s brand Solodyn® his expected to cause a flattening of Acticlate®, ALM’s 
top seller, sales in 2016. Furthermore, Valeant is also competing with ALM as an acquirer of 
dermatology focused businesses.  
 
4.5 - MACROECONOMIC OVERVIEW 
 
Inflation distorts the time value of money, implies costs and CAPEX increases and affects 
cash flow. 
FIGURE 14: ANNUAL INFLATION RATE 
 
Inflation has been stagnant in Europe and US, European Union. Some European countries 
such as Spain are facing deflation. 
Inflation is expected to recoup and keep below 2% for Europe and the US in the near future, 
in line with the European Central bank policy of keeping inflation under control. 
The GDP growth is generally used as performance and overall aggregated spending metric.  
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FIGURE 15: REAL GDP ANNUAL GROWTH RATE 
 
The real GDP growth, adjusted for inflation, was low in 2014 and 2015 for Europe between 
1% and 2%, and estimates to 2020, predict this trend will continue. Emerging markets are 
expected to keep growing at high rates and the US GDP growth is expected to reach 3% in 
2016 and slow down afterwards. 
Regarding exchange rates, it is important to highlight the effect that it can have on 
Multinational company’s revenue which are present in geographies with different currencies.  
FIGURE 16: AVERAGE EURO/USD EXCHANGE RATE 
 
Appreciation and depreciation of exchange rates can result in translation losses and artificially 
increase or decrease sales depending on which currency the company reports in. Aditionally 
for companies that export heavily, appreciations or depreciations of its country’s currency can 
hurt or increase sales volumes.  
The USD has been appreciating against the euro, the average Euro/USD exchange rate for 
2015 1,1. The movement of the Euro/USD is especially important to ALM as the US 
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represents a considerable part of the firm’s revenue, if the firm doesn’t hedge exchange risk, 
exchange rate movements might greatly affect ALM’s income statement. 
 
5 - ALMIRALL’S VALUATION  
 
5.1 - VALUATION METHOD 
 
The valuation method I used to determine the fair value of ALM was a sum of the parts 
valuation. I valued, separately, Almirall’s mature business with a DCF valuation, the R&D 
development pipeline with a multiple valuation suggested by keegan in the literature review 
and the AZN deal income with an NPV valuation, using a discount rate reflecting the 
milestones risk. I complemented my sum of the parts valuation with a relative valuation with 
the purpose of stress testing the FV obtained.  
The price target was 16.20 Euros, well within the ranges of the relative valuation. 
I valued the company as if I were on the 1st of January of 2016, even though some data and 
information was collected after that date, mainly on 29th of February of 2016. 
 
5.2 - MATURE BUSINESS DCF VALUATION 
 
To determine the value of the mature business by a FCFF valuation, I have forecasted an 
income statement, a balance sheet and a cash flow statement to determine the FCF the 
business will generate as a going concern. I estimated an explicit period until the company 
reaches a steady state and a terminal value may be calculated.  
The explicit value of the FCFF valuation is around 141 million Euros and the TV amounts to 
roughly 1517 million Euros, therefore ALM’s mature business value is 1647 million Euros. 
The explicit period considered was 10 years, it ends in 2025. This large explicit period is due 
to the deferred tax liabilities and the income incurring from the AZN deal which will last until 
2025. Thus, after that year the income statement of ALM is normalized in terms of effective 




5.2.1 - RISK-FREE RATE AND MARKET RISK PREMIUM 
 
As mentioned in the literature review, the risk-free rate should be the zero coupon treasure 
bond rate with a long term maturity that pays in the same currency as the investment, 
therefore I consider the plain vanilla fixed coupon German government bond with maturity in 
4th of January of 2031 as the most appropriate instrument of the available fixed income 
instruments. The Yield to maturity at 29th of February was 0.434%, and thus this is the risk 
free rate considered on this dissertation valuation. 
FIGURE 17: COUNTRY DEFAULT SPREAD 
 
For the risk premium I used the historic US market risk premium and added a country specific 
risk premium, the country default spread.  
The historical US market risk premium according to Damodaran in January 2016 is 6.25%, to 
account for the country specific risk I could use the spread derived from the moody’s country 
rating of baa2 for Spain given and its spread of 2.94% but alternatively I considered using a 
market risk premium that reflects the risk by ALM’s geographic presence.  
FIGURE 18: WEIGHTED AVERAGE COUNTRY DEFAULT SPREAD 
 
For this purpose I computed a weighted average market risk premium based on the 
geographic distribution of the company’s revenues, using the average risk premium for North 
America, Western Europe and Spain. Applying this method resulted in a CDS spread of 




Historic Mk risk premium Moddys Rating  Baa2 CDS Weigh Avg.  CDS
6.25% 2.94% 1.37%
Region CDS Weight in revenues Weighed Avg.  CDS 
North America 0.00% 25% 0.00%
Spain 2.94% 32% 0.95%
Western Europe 1.20% 35% 0.42%
Weigh Avg. Spread 1.37%
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5.2.2 - EQUITY BETA AND RETURN ON EQUITY 
 
In line with the literature review, I applied the CAPM regression to compute the raw Beta of 
ALM. The raw beta of the regression of the daily return of ALM against the daily return of 
IBEX over a 5 year period until 29 of February of 2016 was 0,51, once adjusted for the 
market average, the Beta was 0,67. 
The value for the raw Beta is fairly low, due to ALM’s low free-float and trading volume, 
which results in lower volatility compared to the index, therefore I decided that the bottom-up 
beta approach based on peer average would be a better estimate for the sensibility to market 
risk. 
The peer group chosen is composed of mainly European specialty pharmaceuticals and firms 
active in dermatology or aesthetics. All of the aforementioned companies have a free-float 
greater than 60%.  
FIGURE 19: BOTTOM  UP BETA PEER GROUP 
 
For each of the peer companies I computed the raw Beta and unlevered it. Once I calculated 
the unlevered beta for each peer I computed the weighted average by market Capitalization 
and adjusted it to the market Beta. 
FIGURE 20: LEVERED BETA 
 
The unlevered Beta of 0.85 reflects the risk of ALM’s business activities. In line with the 
literature review, I leveraged on the Beta according to ALM’s debt structure to calculate 
ALM’s levered beta.   
Company Free-Float MK Debt/Equity Levered Beta Tax rate Unlevered Beta
Anacor 94.00% 0.00% 0.73 40.00% 0.73
Cynosure 99.60% 0.00% 0.58 40.00% 0.58
Lonza 100.00% 20.57% 1.17 17.92% 1.01
Shire 98.60% 4.63% 0.89 12.50% 0.86
UCB 63.60% 5.84% 0.74 33.99% 0.71
Valeant Pharmaceuticals 94.00% 63.11% 1.26 26.50% 0.86
Faes Farma 98.00% 0.00% 0.73 28.00% 0.73
Grifols 69.00% 29.99% 0.53 28.00% 0.44
Weighted Average 0.85
Unlevered Beta T MK Debt/Equity Levered Beta
0.85 21% 0% 0.85
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Because the company has negative net debt, the levered Beta should be, in theory, lower than 
the unlevered Beta, but since the company announced it will use the excess cash in future 
acquisitions, I considered that in the long-run the net debt will increase. Thus, I considered the 
levered beta is equal to the unlevered beta. 
FIGURE 21: DIFFERENT APPROACHES AND RESPECTIVE COST OF EQUITY 
 
Figure 21 summarizes different Beta methodologies and respective cost of equity. Still I 
considered the most accurate method that reflects ALM’s risk is the bottom-up approach. 
FIGURE 22: COST OF EQUITY 
 
In line with the literature review, I calculated the cost of equity by adding the market risk 
premium for US multiplied by the bottom-up Beta to the risk free rate, then I added the 
weighted average CDS as well. The 𝐾𝑒 obtained was 7.14%. 
 
5.2.3 - COST OF DEBT 
 
Since I assumed that the weight of debt in the capital structure is nonexistent, this implies that 
the cost of debt is irrelevant for valuation proposes. Still using S&P’s rating for the company 
BB- and the respective 3.99% spread and applying it to the already assumed risk free rate of 
0.434%, I reached a value of 4.42% 
Alternatively the company’s debt amounts to 325 million Euros of bonds outstanding traded 
on the EuroBond and US markets, on 29th of February the yield of those bonds was 3.52%. 
The cost of debt could be the yield to maturity on those traded bonds, but for a consistency 
purpose, I calculated the 𝐾𝑑 by adding the S&P spread to the risk free rate, thus the 𝐾𝑑 is 
4.42%. 
 
Beta Approach Beta Ke
Raw Beta 0.51 5.02%
Peer average 0.79 6.75%
Peer average Adjusted Beta 0.85 7.14%
Reuters Beta 0.76 6.45%
Rf Levered Beta Mk Risk Premium Weigh Avg CDS Ke
0.43% 0.85 6.25% 1.37% 7.14%
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5.2.4 - WACC 
 
Since the market value of net debt value is negative and the company intends to spend the net 
cash on acquisitions and might even increase its’ leverage in the future, for this reason I will 
assume an unlevered capital structure, I assumed that the WACC equals 𝐾𝑒 , therefore the 
WACC is 7.16%.  
The reason I didn’t include debt increase for the forecasting period is the fact that the 
company didn’t announce the targets it plans to acquire in the future and the revenue 
increments and synergies that said targets could generate. 
 
5.2.5 - NET WORKING CAPITAL 
 
FIGURE 23: WORKING CAPITAL RATIOS 
 
The current 2015 average payable and collection periods and the inventory to sales ratio were 
used as the drivers of payables, receivables and inventory for the explicit period.  
FIGURE 24: CHANGES IN WORKING CAPITAL 
 
Other current assets accounts for unimportant liquid items, therefore I assumed, for valuation 
purposes, these items remain stable. Other current liabilities accounts mostly for wages and 
salary payable and research related loans, thus I have forecasted other current liabilities using 
salaries payable as a driver by using the average of wages and salaries payable in one year 
over total wages and salaries. 
 
 
Average Payble Period (days) Average Collection Period (days) Inventory to Sales (%)
383 64 13%
Year 2015 2016E 2017E 2018E 2019E 2020E
Changes in working capital -59 13 5 5 3 3
Changes in inventory 7 6 5 6 5 4
Changes in receivables -107 8 7 8 7 6
Changes in payables -8 -5 -8 -9 -10 -7
Changes in other current assets -4 0 0 0 0 0
Changes in other current liabilities 54 4 0 0 0 0
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5.2.6 - CAPEX AND AMORTIZATION & DEPRECIATION 
 
The CAPEX of pharmaceutical companies include substantial investment in intangibles 
assets. I forecasted the CAPEX to equal amortization and depreciation from 2018 onwards. 
FIGURE 25: AMORTIZATION & DEPRECIATION PROJECTIONS 
 
FIGURE 26: CAPEX PROJECTIONS 
 
The higher CAPEX for 2016 is due to the acquisition of ThermiGen in February 2016 and 
Poli Group in November 2015, which will be paid for in 2016, both were recognized in 
business acquisitions. The sale of ALM Mexico subsidiary for 50 Million Euros to Grünenthal 
Group was recognized on disposals on 2016 and 2017. 
The company plans to spend between 500 and 700 million Euros in acquisitions in the near 
future, but because no deal information was made public so far, the forecast figures imply that 
the company invests to replace existing capacity, thus CAPEX offsets Depreciation after 
2017.  
Depreciation is set as fixed percentage of depreciable and amortizable Assets (PPE and 
intangibles) at around 12.9%. 
 
5.2.7 - DIVIDENDS, RESERVES AND RETAINED EARNINGS 
 
FIGURE 27: EQUITY RATIOS PROJECTIONS 
 
Year 2015 2016E 2017E 2018E 2019E 2020E
Amortization & Depreciation 74 70 120 124 124 124
Year 2015 2016E 2017E 2018E 2019E 2020E
Capex 70 509 155 124 124 124
intangible assets 14 52 89 92 92 92
PPE 13 18 31 32 32 32
Financial Assets 30 0 0 0 0 0
Business acquisitions 14 439 35 0 0 0
Disposals -62 -46 -4 0 0 0
Intangible assets and PPE -64 -46 -4 0 0 0
Financial Assets 0 0 0 0 0 0
Exclusion from consolidation 2 0 0 0 0 0
Year 2015 2016E 2017E 2018E 2019E 2020E
Legal reserve 20% 20% 20% 20% 20% 20%
Retained earnings 73% 80% 77% 77% 77% 77%
Div Payout ratio 27% 20% 23% 23% 23% 23%
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The company announced a dividend payment of 33 million, which accounts for payout ratio 
of 23%, a ratio that I assumed will keep stable in future years. The legal reserve corresponds 
to 20% of issued capital. 
FIGURE 28: DIVIDEND PAYMENT  ESTIMATES 
 
 
5.2.8 - REVENUE FORECAST 
 
In order to forecast revenues, I used both market research information and company 
information for the main products, therapeutic areas and acquired firms products’ revenue 
potential. Figure 29 displays revenue projection for the whole business and for some 
therapeutic areas and acquired businesses.  
FIGURE 29: REVENUE PROJECTIONS 
 
The main therapeutic areas are dermatology, gastrointestinal and respiratory. For dermatology 
and aesthetics I forecasted growth based on the products expected growth, and therapeutic 
market growth projections, for therapeutic areas where the company plans to divest and 
anticipates a further decline in sales, I estimate that sales decrease in line with the average of 
the last 5 years. 
Year 2015 2016E 2017E 2018E 2019E 2020E
Div Paid 35 33 33 34 36 38
Year 2015 2016E 2017E 2018E 2019E 2020E
Total Revenues 769 859 897 940 978 1007
Total Sales 685 744 786 832 875 909
YoY -13% 9% 6% 6% 5% 4%
Derma Europe 145 152 159 168 176 186
YoY 1% 5% 5% 5% 5% 5%
Derma US 150 162 182 203 216 231
YoY 35% 8% 12% 11% 7% 7%
ThermiGen 30 53 77 100 111
YoY 100% 78% 44% 30% 11%
Poli Group 85 93 100 108 116
YoY 100% 9% 8% 8% 8%
Respiratory 105 67 62 57 53 49
YoY -50% -36% -7% -7% -7% -7%
GastroIntestinal 123 103 100 98 96 95
YoY -6% -16% -3% -2% -2% -2%
Other Sales 162 145 137 130 125 121
YoY -15% -10% -6% -5% -4% -3%
O ther income 84 115 111 107 103 98
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For the acquisition of ThermiGen and Poli Group, I used the estimates that the company 
provides, which states that both acquired portfolios can s more than 100 million in sales in 
2020.  
I expect Poli Group and ThermiGen to account for around 25% of total sales by 2020.  
FIGURE 30: TOP SELLERS’ PROJECTIONS 
  
Figure 30 presents the company top products, for each of them I forecasted sales figures using 
the respective therapeutic market growth as a driver and information on product patent cliff 
when disclosed by the company, when patent expiration has occurred or is imminent I 
forecast that sales decline in line with estimates given by the company or based on last years 
decline in sales.  
For the company main product Acticlate® which accounted for 14% of the company sales, I 
forecasted a flat performance for 2016, in line with company guidance, justified by increasing 
competition from Valeant’s brand Solodyn® and generics. 
 
Year 2015 2016E 2017E 2018E 2019E 2020E
Monodox®/Acticlate® 97 97 104 112 121 130
YoY 43% 0% 8% 8% 8% 8%
Ebastel® and other 62 57 52 48 44 40
YoY -8% -8% -8% -8% -8% -8%
Almogran® and other 18 16 15 14 13 12
YoY -59% -8% -8% -8% -8% -8%
Airtal® and other 28 26 24 22 20 18
YoY -8% -8% -8% -8% -8% -8%
Decoderm® and others 23 25 27 29 31 34
YoY -4% 8% 8% 8% 8% 8%
Cordran® 28 30 32 35 37 40
YoY 17% 8% 8% 8% 8% 8%
Almax® 24 26 27 29 31 33
YoY 10% 7% 7% 7% 7% 7%
Balneum® 17 18 19 20 21 22
YoY 5% 5% 5% 5% 5% 5%
Tesavel® & Efficib® 44 42 40 38 36 35
YoY -5% -5% -5% -5% -5% -5%
Solaraze® 40 39 38 37 37 36
YoY 3% -2% -2% -2% -2% -2%
Parapres® 6 0 0 0 0 0
YoY -66% -100%
Sativex® 13 14 15 16 17 18
YoY -12% 7% 7% 7% 7% 7%
Ciclopoli® 0 34 37 40 43 46
YoY 9% 8% 8% 8%
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FIGURE 31: REVENUE BREAKDOWN PROJECTIONS 
 
High growth in dermatology sales is due to the company’s strategic direction, particularly in 
the US. The US and European dermatology business is expected to increase its share to 26% 
and 28% of total sales, respectively, in 2020, including the increments in dermatology sales 
Poli Group will generate, 60% of the group’s revenue is on dermatology.  
The abrupt sales breakdown in the respiratory portfolio in 2016 is due to the disposal of 
Plusvent®. 
Aesthetics, a therapeutic that ALM entered recently with the acquisition of ThermiGen will 
account for 12% of sales in 2020. Respiratory and gastro and metabolism will keep 
decreasing their weight in the company’s portfolio, by 2020 they will represent 8% and 10%, 
respectively. For values table see Appendix XIII. 
 
5.2.9 - OTHER INCOME 
 
Other income includes deferred income recognition from AZN transaction and milestone 
related payments. I recognized the deferred income in equal amounts for 10 years up until 
2025 of the 201.721 million Euros to be recognized. The amounts equal 20 million Euros 
each year. The AZN linked milestones payments are recognized as equal amounts, as well, for 
10 years until 2025, the amount recognized is the expected value linked to the probability of 
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reaching the milestones, 95 million Euros multiplied by the probability of receiving the full 
amount, the probability decreases as the years advance. 
 
5.2.10 - FINANCIAL RESULTS AND TAXES 
 
Financial results are set as a fixed percentage of net Debt for 2015. This percentage is applied 
to the net debt of the previous year to determine the current years’ financial results.  
I estimated the tax rate for the forecasted period by taking into account the deferred tax 
liabilities and assets, ALM has tax credits resulting from R&D activities and has considerable 
tax liabilities as well, according to the notes in the balance sheet, the company expects to 
offset them in 10 years, thus I will calculate the effective tax rate by deducing to the estimated 
corporate tax rate the recognized tax credits per year and the deferred tax liability recognized 
per year.  
FIGURE 32: TAX CREDITS AND DEFERRED TAXES PROJECTIONS 
 
Tax credits are a recurrent event in ALM’s activity and I estimated that the tax credit per year 
will be the average of the last 5 years, 27 million Euros. 
FIGURE 33: WEIGHTED AVERAGE CORPORATE TAX RATE 
 
To the 29.89% estimated corporate tax rate applied on taxable income, I subtracted the net 
effect from offsetting tax assets and liabilities, to the income tax due. The corporate tax rate 
was calculated by doing the weighted average of ALM’s taxable income by geography, 
Year 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Deferred Tax Assets 317 312 307 302 297 292 287 282 277 272 266 261
Tax Credit Recognized 34 32 32 32 32 32 32 32 32 32 32 32
Tax Credit (R&D) 12 27 27 27 27 27 27 27 27 27 27 27
Deferred Tax Liabilities 125 113 100 88 75 63 50 38 25 13 0 0
Deffered Tax Liabilities Recognized1 13 13 13 13 13 13 13 13 13 13 0
Net Effect on Tax 33 19 19 19 19 19 19 19 19 19 19 32
Geography T Weight % Net Income Weigh Avg T
Corporate Tax US 40% 31% 12.59%
Corporate Tax EU 22.50% 34% 7.71%
Corporate Tax Spain 28% 34% 9.59%
Average Tax rate 29.89%
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considering the US corporate tax rate for Aqua pharmaceuticals profit, Spain and EU 
corporate tax for the rest of the consolidated group. 
FIGURE 34: EFFECTIVE TAX RATE 
 
I extended the effective tax estimation period until 2025, by that year the deferred tax 
liabilities will be completely recognized. From that year onwards, I consider that the effective 
tax rate is the corporate tax rate minus the average tax credit, which results in an effective tax 
rate of 12.5%, which is the effective tax rate assumed for the terminal value calculation. 
 
5.2.11 - GENERAL AND ADMINISTRATIVE COST AND R&D 
 
In my forecasts, general and administrative expenses are expected to decrease slightly, due to 
the increasing weight of the US dermatology in the company business portfolio, the US 
dermatology business unit as lower operating costs. 
FIGURE 35: COST BY BUSINESS UNITS 
 
Not only has the US dermatology business had higher operating margin than the rest of 
ALM’s business but in fact without the other income from royalties and agreements with 
other firms, mainly AZN, the EBITDA margin of the rest of ALM’s business would be fairly 
low, around 5%, revealing the lack of competitiveness of ALM’s more mature products. 
The recent Acquisitions also affected the forecasted general and administrative costs and 
R&D costs. 
FIGURE 36: GENERAL & ADMINISTRATIVE COSTS, R&D AND COGS 
 
Year 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Effective T 23.64% 20.91% 18.82% 19.42% 20.01% 20.40% 20.57% 20.67% 20.85% 21.04% 21.23% 12.45%
Gen & Admin Costs R&D COGS
Poli Group 40% 10% 20%
Rest of Business 43% 10% 38%
Thermigen 40% 10% 40%
Derma USA 27% 10% 9%
Year 2015 2016E 2017E 2018E 2019E 2020E
Gen. & Admin. costs 41% 39% 39% 38% 38% 38%
R&D 10% 10% 10% 10% 10% 10%
COGS 31% 29% 28% 28% 28% 27%
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COGS and General and admnistritive costs are expected to improve slightly in 2016 and in 
the following years, supported by the growth of dermatology. I estimated R&D to be kept 
constant at 10% according to the company guidance. 
ALM’s margins have an important contribution of other income from the recent AZN deal, if 
this is excluded the margins are substantially lower. 
FIGURE 37: EBIT AND EBITDA MARGINS (NORMAL AND ADJUSTED) 
 
 
5.2.12 - ADJUSTMENT TO EBIT 
 
Due to the effect of the AZN transaction, I have adjusted the EBIT by excluding both the 
income streaming from reaching the milestones of the AZN deal and the differed income 
recognized from the transaction in 2014. The adjusted EBIT will be used to calculate the 
NOPLAT. 
FIGURE 38: ADJUSTED EBIT 
 
 
5.2.13 - EXPLICIT PERIOD VALUE AND TERMINAL VALUE 
 
The explicit period value reached was around 140 Million Euros. The FCFF in the first year is 
low due to the CAPEX in acquisitions of Poli Group and ThermiGen in 2016. 
 
 
Year 2015 2016E 2017E 2018E 2019E 2020E
EBITDA margin 30% 37% 37% 37% 36% 35%
EBITDA margin (Ex. other income from deals) 19% 22% 23% 24% 24% 25%
EBIT margin 19% 28% 22% 22% 22% 22%
EBIT margin (Ex. other income from deals) 8% 13% 8% 9% 10% 11%
Year 2015 2016E 2017E 2018E 2019E 2020E 2021E 2022E 2023E 2024E 2025E 2026E
EBIT 131 208 171 181 191 198 201 202 205 208 212 143
EBIT (Excluding Transaction effects) 52 94 60 73 87 100 107 113 120 128 135 143
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FIGURE 39: EXPLICIT PERIOD VALUATION 
 
The explicit period ends in 2025, the period where I concluded the company will enter in 
steady state, the effects from the acquisitions and ALM’s strategy revamping will be 
complete. From 2025 onwards I used a perpetuity valuation of the company. 
FIGURE 40: NOMINAL AND REAL GROWTH RATES IN 2020 
  
To calculate the terminal value, I used a terminal growth of 2.98%, the median between the 
weighted averages of nominal and real GDP growth projections of Europe, USA and Spain in 
2020 according to each geography weight in revenues, the nominal and real GDP g are 3.93% 
and 2.93%, respectively. The pharmaceutical sector is predicted to grow at around 7% to 
2020, and has regularly outperformed GDP growth globally on average but in the long run I 
expect it to converge to the GDP growth. 
Some analysts argue that the pharmaceutical sector in the future will suffer with price limits 
and unfavorable regulation, but the ageing of the population will increase volume sales, and 
Year 2015 2016E 2017E 2018E 2019E 2020E 2021E 2022E 2023E 2024E 2025E
Total Revenues 769 859 897 940 978 1007 1030 1052 1077 1103 1130
Total Sales 685 744 786 832 875 909 936 964 993 1022 1053
YoY -13% 9% 6% 6% 5% 4% 3% 3% 3% 3% 3%
Other income 84 115 111 107 103 98 94 88 85 81 77
Cost of Sales -215 -217 -224 -233 -242 -248 -256 -263 -271 -279 -288
R&D -66 -72 -76 -81 -85 -88 -91 -93 -96 -99 -102
General and Administrative  costs -280 -290 -304 -320 -335 -347 -357 -368 -379 -390 -402
Other op. expenses -3 -2 -2 -2 -2 -2 -2 -2 -2 -2 -2
EBITDA 206 278 291 304 314 321 324 325 329 332 336
Amort & Dep -74 -70 -120 -124 -124 -124 -124 -124 -124 -124 -124
EBIT 131 208 171 181 191 198 201 202 205 208 212
EBIT (Excluding Transaction effects) 52 94 60 73 87 100 107 113 120 128 135
YoY 0 1 0 0 0 0 0 0 0 0 0
Taxes -16 -20 -11 -14 -17 -20 -22 -23 -25 -27 -29
NO PLAT 37 74 49 59 70 80 85 90 95 101 107
Amortization&Depreciation 74 70 120 124 124 124 126 129 131 134 137
Changes in NWC 59 -13 -5 -5 -3 -3 -3 -3 -3 -4 -4
Net CAPEX -8 -458 -149 -121 -121 -120 -122 -125 -127 -130 -132
FCFF 162 -327 15 57 70 80 85 91 96 102 107
Discount factor 93% 87% 81% 76% 71% 66% 62% 58% 54% 50%
Wacc 7.14%
DCF Explicit 141














the innovation in the sector will provide substantially growth opportunities that might offset 
the control on prices.  
Inflation may only partially affect ALM’s future sales, implying that the terminal growth rate 
should be between the nominal and real GDP growth rates, therefore I concluded the median 
between the real and nominal growth rate for 2020 to be the most accurate.  
FIGURE 41: TERMINAL GROWTH RATE IN 2020 
 
I considered that from 2020 onwards, the company will be in a steady state of growth, but due 
to the increments of AZN deal and the deferred tax liabilities ending in 2025, I computed the 
TV on 2025. The FCFF for the terminal year is higher due to the effective tax rate being 
lower on the long term due to tax credits. 
FIGURE 42: TERMINAL VALUE 
 
The terminal value calculated was around 1517 million Euros, accounting for most of ALM 
mature business’ value. 
 
5.3 - R&D PIPELINE VALUATION 
 
To value the products under development, I have focused on the projects, on which I have 
visibility on peak sales and are expected to launch before 2021. 
Nominal Median Real
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FIGURE 43: R&D VALUATION 
 
For establishing peak sales, the traditional method proposed in the literature review was not 
applicable. Although I managed to find suitable studies on disease incidences, in most cases I 
lacked information to establish a cost per patient and a market share that the company would 
have on the addressable market.  
Instead of estimating a market model I used figures that ALM’s investor relations provided 
me based on competitors and the range of peak sales they believed were achievable for their 
key R&D catalysts. My visibility is thus restricted to 4 medical compounds under 
development, LAS 41008, P-3058, P-3073, P-3074, which are according to the company, the 
most promising. 
To perform the valuation, in line with my Literature review, I used the P/E method proposed 
by Keegan. I estimate a launching date based on the stage of each compound, considering that 
5 years after launching the products would reach peak sales. I considered the average 
profitability rate of the industry based on estimates provided by Damodaran to estimate peak 
earnings.  
To determine the NPV of each compound, I applied a P/E multiple taken from the company 
peers and also used in the relative valuation and discounted the value to the present, using the 
estimated ALM’s WACC.  
Peak sales were estimated by using information provided by the company and comparing the 
products to main competitors. The company guidance estimates that LAS41008 might 
generate peak sales of 35 to 50 million, in line with existing competitor Fumaderm®. For P-
3058 whose main competitor Jublia® from Valeant generated 500 million in sales in Europe 
alone, I estimated that sales could peak at 70 Million once the product is launched in line with 
the company guidance. 
R&D Project Indication Status Launch Prob Peak sales (Usd) Profitabilty NPV(Eur)
LAS41008 Plaque Psoriasis III 2017 64% 50 8% 53
P-3058 Onychomycosis III 2020 64% 68 8% 59
P-3073 Nail psoriasis III 2020 64% 54 8% 47
P-3074 Male andro alop II 2020 41% 38 8% 21






 P-3058, alongside the other pipeline projects acquired from Poli Group benefits from the 
HPCH formulation, which gives it significant advantage against existing products, are also 
expected to perform well in the market. 
I considered using real option valuation but with the information I had available, an option 
valuation was not applicable. I lacked visibility on R&D costs attributable to each project, 
thus I couldn’t estimate a strike price. Furthermore, although I had peak sales estimation, I 
lacked information to realistically estimate an NPV of the cash-flow the patent will generate 
in the future, the underlying asset in real option valuation.  
Concluding, the value that I attributed to ALM’s R&D through the model is 181 million 
Euros. 
 
5.4 - NET CASH 
 
On 29th of February the net cash position was around 87 million Euros. I subtracted the value 
of cash and cash equivalents to the value of debt, additionally I included the cash outflows of 
Poli Group and ThermiGen acquisitions and the cash inflows from the sale of the Mexico unit 
to Grünenthal, thus the initial Net cash position at the end of 2015 of 484 million Euros 
decreased to 87 million Euros.  
For valuation purposes, considering the 1st of January as the present date, ALM has a net cash 
position of 484.5 million Euros. 
 
5.5 - AZTRAZENECA DEAL VALUATION 
 
Of the 1.22 Billion USD related to milestones of the AZN deal, 170 million were already 
received. The remaining 1050 Million USD are expected to be paid in the next 10 years. The 
payment is dependent on certain development, sales and launch milestones being met. In line 
with the company guidance, LAS190792 progress is the critical factor in the milestones. The 
amounts of sales related to milestones were not disclosed by the company.  
According with ALM’s Investor relations, the probability of receiving the 1.05 Billion USD 
outstanding is between 80% and 85%. 
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To value the AZN deal milestone payment I assumed, in line with company estimates, that the 
amount outstanding would be paid in equal amounts of 105 million USD or 95 million Euros 
at the average exchange rate for 2016, until 2025. Furthermore I adjusted the value for the 
effective tax rate, which resulted in an average payment after tax of 75 million Euros per year. 
I assumed that 80% of the total 1050 million USD would be paid as base scenario but the 
probability would decrease further as the years progressed. 
  
FIGURE 44: AZTRAZENECA COST OF CAPITAL 
 
To discount the development milestone-related payments, I used AZN’s WACC, implying 
that the risk of these cash flows is tied to AZN ability to fulfil the sales and R&D 
development milestones in the joint projects. 
FIGURE 45: AZTRAZENECA  DEAL INCOME VALUATION 
 
Once discounted the total after tax payments and adjusted for the probability, amounted to 
603 Million Euros, which I assumed was the fair value for this part of the valuation. 
The Euro/USD exchange rate fluctuations may affect the value of the Astra Zeneca deal, this 
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2016 105 95 75 100% 75 95% 71
2017 105 95 77 96% 74 91% 67
2018 105 95 76 92% 70 87% 61
2019 105 95 76 88% 67 83% 55
2020 105 95 75 82% 62 79% 49
2021 105 95 75 78% 59 75% 44
2022 105 95 75 72% 54 72% 39
2023 105 95 75 68% 51 68% 35
2024 105 95 75 64% 48 65% 31
2025 105 95 75 60% 45 62% 28
Total 1050 946 753 80% 603 480
60 
 
5.6 - TARGET PRICE AND RECOMMENDATION 
 
The target price is the fair value that results from the sum of the parts valuation. 
The criteria that I used to make the recommendation is based on the coefficient of variation of 
the daily closing prices of the last year 2 years 2015 and 2014, which reflects the dispersion of 
share prices in relation to the average of the last two years, the interval was chosen due to the 
fact that those years incorporate the beginning of the change in the company strategy, thus a 
similar period to the near future, in how the market values the company. The coefficient of 
variation for the last 2 years was 18.5% and target price is 16.20 Euros, the current price is 
18.4, above the range the of the coefficient of variation, 14.70 to 17.70 , thus the 
recommendation is to SELL if the current price was within or below that range, the 
recommendation would be to HOLD or BUY, respectively. 
 
5.7 - SENSITIVITY ANALYSIS 
 
I performed the sensitivity analysis based on growth of sales, terminal growth rate, expenses 
as percentage of sales such as cost of sales, R&D and general and administrative costs, 
probability of receiving the milestone payments related to the AZN deal, on future peak sales 
of company’s current R&D projects and the Euro/USD exchange rate variations and its 
impact on US dermatology subsidiary sales. 
Even though the company states in its annual accounts that it hedges currency risk, it doesn’t 
explain how it does it in detail, as a matter of prudence, I decided to include a sensitivity 
analysis on the impact of movements of the Euro/USD on the US dermatology business unit 
revenues. I projected two alternative scenarios where the USD appreciates 3% and depreciates 
3% per year until 2020.  
Additionally the Sensitivity analysis includes movements of the risk free rate, which is 
currently historically low, of +1% and +2%.  
The general and administrative costs, R&D and cost of sales were also considered, with 
changes of 1% relative to base scenario in the range from -2% to 2% of sales from the base 
assumed percentage of sales.  
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Assumptions on current R&D projects future peak sales were also tested in a range of -25% to 
+25% of base assumed peak sales.  
Terminal value growth variations to the nominal and real GDP g were projected, as well as 
explicit period growth variation of +1% and -1% in relation to the base assumed rate.  
The sensitivity analysis included variations of the probability of receiving the AZN payment 
to 75% and 84% compared to the initially assumed 80%,  
In appendix XII there are tables showing combined assumptions changes and respective fair 
value variations. The price is mostly sensible to growth rate variations, mainly the explicit 
period growth rate due to the cost structure aside from COGS remaining equal and thus low 
variations in growth rate have a large impact on share price. The 𝑅𝑓, exchange rate variations 
and cost variation also cause significant changes in fair value. Due to the many assumptions 
tested, the sensitivity analysis contemplates a wide range of FV, from the absolute worst 6.64 
Euros to the absolute best 28.92 Euros. 
 
5.8 - RELATIVE VALUATION 
 
To perform relative valuation of ALM, I used the P/E, EV/EBITDA and EV/SALES 
multiples.  




EV/EBITDA Historic P/E EV/SALES
Forward 
EV/EBITDA Forward P/E 
Forward 
EV/SALES
Lonza 13.27 31.03 2.68 11.32 19.20 2.45
Shire 15.20 30.70 6.71 9.14 11.89 4.44
UCB 20.56 60.56 4.24 14.99 24.94 3.47
Faes Farma 14.02 22.87 3.24 11.93 0.00 2.98
Grifols 15.76 54.93 4.65 12.94 19.66 3.93
ROVI 22.69 35.91 2.93 16.34 24.68 2.38
Dermira 0.00 0.00 112.69 0.00 0.00 76.50
pharma Mar 34.13 83.11 3.09 0.00 0.00 0.00
Aclaris 0.00 0.00 0.00 0.00 0.00 0.00
Anacor 0.00 0.00 60.44 111.56 194.39 16.16
Valleant 13.53 0.00 6.18 7.86 2.98 3.58
Cynosure 18.04 63.81 2.62 13.17 28.51 2.10
Zeltiq 175.01 27.84 4.19 23.87 101.56 2.64
Average 18.58 45.64 4.05 13.51 29.18 3.11
Median 17.08 35.91 4.22 13.06 24.68 3.47
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To have an adequate benchmark, I have gathered a peer group composed of medium sized, 
specialty pharmaceutical companies and firms focused on dermatology and aesthetics. Figure 
46 presents the multiples for each of those companies taken from Thomson Reuters. For each 
multiple I computed the average excluding outliers (in bold) and the Median. 
As discussed in the literature review, I used both forward and trailing multiples. The results 
were adjusted in order to don’t reflect the other income from the AZN deal, as such income is 
non-recurrent and it will end in 2025, still I added the AZN income value already obtained 
separately to reach the fair value. I adjusted the net income by subtracting the AZN income 
from EBIT and apply the effective tax rate to that adjusted EBIT. 
In line with the literature review, I used the median instead of the simple average of the 
company’s peer as the multiple to better exclude the effect of the outliers. 
FIGURE 47: FORWARD AND TRAILING MULTIPLES VALUATION 
 
Using the forward multiple approach, the fair value should be between 13.89 and 20.51. The 
fair value obtained through the sum of the parts valuation is well within this range but higher 
than the Forward P/E, which is explained by the growth potential that the company has in the 
long run, with the acquisitions made, not being fully reflected in 2016 earnings.  
 
6 - INVESTMENT BANK REPORT COMPARISON 
 
I choose to compare my report with Credit Suisse equity research report published on the 23th 
of February, 2016.  
The target price on Credit Suisse report is 14 Euros considering a 12 month period, it implies 
a downside of 16.5%, still Credit Suisse maintains a NEUTRAL rating stating: “Our Neutral 
Trailing Almirall EV/EBITDA EV/Sales P/E EV Equity FV per share
EBITDA 122 17.08 0 0 2558 3043 17.59
Revenue 685 0 4.215 0 3367 3851 22.27
Earnings 68 0 0 35.91 3124 3568 20.63
AstraZeneca Value 480
Forward Almirall EV/EBITDA EV/Sales P/E EV Equity FV per share
EBITDA 163 13.06 0 0 2611 3095 17.89
Revenue 744 0 3.47 0 3063 3547 20.51




rating reflects the lack of visibility on bolt-on and M&A deals to achieve its strategy and 
clarify the mid-term outlook”. Credit Suisse uses an NPV based Methodology called 
PharmaValue NPV methodology, based on sales probability, on which it states that the 
company is traded on 30% premium to equity NPV. The 9.6 NPV per share implies that 
Credit Suisse ALM NPV is 1661 million Euros afterwards the cash was added to obtain the 
equity NPV per share to which a premium of 30% is applied. 
Credit Suisse stock rating are to OUTPERFORM (BUY), NEUTRAL (HOLD) and 
UNDERPERFORM (SELL) and are based on comparison with the relevant benchmark, 
which are generally companies of the same sector.  
Additionally, Credit Suisse recommends to Overweight, Market Weight or Underweight, 
which are related to the analyst’s expectations for the sector’s fundamentals, if it is favorable, 
neutral or cautious over the next 12 months, respectively. 
The differences between this dissertation and Credit Suisse equity research report includes the 
revenues forecast. In this dissertation, revenue growth is higher compared with Credit Suisse 
estimated, the CAGR for 2015-2020 is around 6% compared with 4% from the Credit Suisse 
report.  
Credit Suisse EBIT margin forecast are lower than what I considered, mainly due to higher 
increments in other income that I am considering from the AZN deal. SG&A/SALES are 
similar for 2016, but from that point onwards this dissertation forecast higher SG&A/SALES, 
this is due to an increase in depreciation & amortization resulting from the inclusion of 
ThermiGen and Poli Group assets in intangibles and PPE.  
Credit Suisse does not disclose the discount rate used on its NPV valuation, thus I can’t 
compare with the WACC used in this dissertation.  
This dissertation valuation includes R&D components valued at 181 million Euros, which are 
not contemplated by the Credit Suisse valuation.  
Other income is also a key differentiator of both analyses, in this dissertation, I assumed that 
both the differed income and the income received from milestones is going to be recognized 
and received in probability weighted equal amounts until 2025, while Credit Suisse reports 
makes different assumptions on other income with higher values in 2017 and 2018.  
Another noticeable difference refers to the fact that credit Suisse Report doesn’t include 
retirement benefit obligations in net debt. 
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Concluding, Credit Suisse values the company as a whole based on a peer based premium on 
the equity NPV. It does not value the proceedings of AZN transaction and R&D components 
separately. The recommendation method is also different, which results in Credit Suisse 
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I: Peer List for Multiples and Beta calculations 
- LONZA GROUP AG - Swiss biopharmaceutical and chemical multinational 
company, leader in supplying biopharmaceuticals to the pharmaceutical industry.  
- SHIRE PHARMACEUTICALS PLC - Irish-headquartered specialty 
Biopharmaceutical Company, it focus on behavioral health, rare conditions, 
gastrointestinal and regenerative medicine. 
- UCB SA - Belgian multinational bio pharmaceutical, it focus on R&D mainly on 
specialty pharmaceuticals, neurology and oncology are the company’s main concerns.  
- FAES FARMA SA - Spanish pharmaceutical and chemical company, it 
commercializes pharmaceutical products and raw materials, it exports to more than 60 
countries.  
- GRIFOLS SA – Spanish specialty pharmaceutical company, specialized in blood 
plasma based products, on which it is the world leader, it also markets diagnostic 
products.  
- LABORATORIOS FARMACEUTICOS ROVI SA- Spanish pharmaceutical 
company, which markets both proprietary and licensed products.  
- DERMIRA Inc. - US based dermatology focused pharmaceutical company.  
- PHARMA MAR SA - Spanish pharmaceutical company focused on oncology.  
- ACLARIS THERAPEUTICS Inc. - US based dermatology focused pharmaceutical 
company. 
- VALEANT PHARMACEUTICAL INTERNATIONAL INC. - Canadian based 
multinational company, specialized in dermatology among other therapeutic areas. 
- ANACOR Pharmaceutical Inc. - US based aesthetic company. 
- CYNOSURE INC. - US based aesthetic company. 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































IV: ALMIRALL’s Cash Flow Statement 
 









Cash Flow Statements 2016E 2017E 2018E 2019E 2020E 2021E 2022E 2023E 2024E 2025E
Operating Income 208 171 181 191 198 201 202 205 208 212
Depreciation & Amortization -70 -120 -124 -124 -124 -124 -124 -124 -124 -124
Changes in NWC -13 -5 -5 -3 -3 0 0 0 0 0
Investment Other Operating Assets 75 178 181 179 178 179 180 179 179 178
O perating Cash Flow 201 224 233 243 249 256 258 260 263 266
CAPEX -509 -155 -124 -124 -124 -124 -124 -124 -124 -124
Disposals 46 4 0 0 0 0 0 0 0 0
Cash Flows from Investing Activities -463 -151 -124 -124 -124 -124 -124 -124 -124 -124
Equity Instruments -35 -33 -33 -34 -36 -38 -38 -38 -39 -40
Liability Instruments 0 -4 0 0 0 -316 0 0 0 0
Net Cash Flows from Financing Activities -35 -37 -33 -34 -36 -353 -38 -38 -39 -40
Cash Change -296 37 77 85 89 -221 96 98 100 103
Products Name Medical Condition Therapeutic Area Proprietary/Licensed
Eklira® and other (aclidinium bromide) COPD Pulmonary/Respiratory Diseases Proprietary
Ebastel® and other (ebastine) Allergy Pulmonary/Respiratory Diseases Proprietary
Oral Acne franchise (Monodox / Acticlate) Acne Dermatology Proprietary
Tesavel® & Efficib® (sitagliptine) Diabetis Type II Endocrinology Licensed
Almogran® and Other (Almotriptan) Migraine Neurology Proprietary
Solaraze® (diclofenac sodium) Actinic keratosis Dermatology, Oncology Licensed
Plusvent® (salmeterol & fluticasone) COPD and Asthma Pulmonary/Respiratory Diseases Licensed
Airtal® and Other (aceclofenac) Pain Musculoskeletal Proprietary
Decoderm® and others (flupredniden) Mycotic Dermatitis Dermatology Proprietary
Cordran® (flurandrenolide) Steroid responsive dermatoses Dermatology Proprietary
Almax® (almagate) Heartburn Gastroenterology Proprietary
Parapres® (candesartan cilexetile) Hearth Failure, Hypertension Cardiology/Vascular Licensed
Balneum® (urea oil) Dry and Itchy skin Dermatology Proprietary
Sativex® (delta-9-tetrahy drocannabinol) Multiple Sclerosis Neurology, Musculoskeletal Licensed
Ciclopoli® Onychomycosis Dermatology Proprietary
Veltin® Acne Dermatology Proprietary
Altabax® Impetigo Dermatology Proprietary
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VII: Exchange rate risk 
Exchange rate is present in ALM’s activity, mainly in cash inflows from US sales, the 
payments related to AZN deal, clinical trials paid for in different currency, raw material 
purchases, royalty payments in yens and payments made in local currency by the ALM’s 
subsidiaries in Mexico, the UK, Poland, Canada, Denmark and the US. 
Exchange risk affects 34.87% of revenues and 31.14% of cost of goods sold and other 
operating costs. The company foresees collections and payments in foreign currency on a 
quarterly basis. In 2015,  
ALM reduced its exposure on foreign exchange risk on higher volume commercial 
transactions by arranging hedge contracts related to yen purchases of raw materials and cash 
inflows from US revenues, additionally any cash surplus in foreign currency are sold to avoid 
exchange rate volatility that might affect the income statement. 
VIII: Market Capitalization 
In 29 of February, the Market capitalization was 2931,15 million Euros. ALM has 172951120 
shares outstanding, the free float is 33,10% and the price close in 4 of January of 2016 was 
18.4 Euros. 
66.64% of shares are owned by WALTON, S.L. a private real estate family based in Madrid. 
IX: Financial Debt 
In March 2014, ALM issued 325 million Euros in bonds with maturity in 2021.  
The book value of non-current financial liabilities is 316 Million. The bonds are traded in the 
United States and in the Euro Bond Market. 
In the beginning of 2016 the total book value of financial debt, current and non-current was 
383,5 Million Euros. 
X: Current Investments, Cash and Cash Equivalents 
Liquid assets in the balance sheet include current investments, cash and cash equivalents. It 
mainly includes shares and debt securities in other companies, deposits with short maturities, 
investments in fixed income and equity funds, future payments related to the AZN deal and 
available for sale financial assets.  
The total amount of current investments cash and cash equivalents was 868 million Euros. 
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XI: ALMIRALL’s Management 
Management includes CEO Eduardo Sanchiz, CFO Daniel Martinez and Global Business 
executive Alfonso Ugarte. 











-2% -1% Base +1% +2%
-2% 19.09 18.28 17.48 16.67 15.86
-1% 18.45 17.65 16.84 16.03 15.23
Base 17.82 17.01 16.20 15.40 14.59
+1% 17.18 16.37 15.57 14.76 13.95











) General and Administrative  Costs (% of Sales)
+25% Peak Sales Base -25% Peak Sales
-2% 17.69 17.43 17.16
-1% 17.08 16.81 16.55
Base 16.46 16.20 15.94
+1% 15.85 15.59 15.33
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XIII: Therapeutic Area as Percentage of Sales. 
 
XIV: Cost Structure as a Percentage of Sales 
 
XV: ALMIRALL’s US Dermatology Unit EBITDA Margin 
 





Year 2011 2012 2013 2014 2015 2016E 2017E 2018E 2019E 2020E
Dermatology Europe 15% 19% 19% 18% 21% 27% 27% 27% 27% 28%
Dermatology USA 0% 0% 0% 14% 22% 22% 23% 24% 25% 26%
Aesthetics 0% 0% 0% 0% 0% 4% 7% 9% 11% 12%
Respiratory 24% 25% 30% 27% 15% 11% 10% 9% 9% 8%
Gastro & Metabolism 20% 22% 21% 17% 18% 14% 13% 12% 11% 10%
Other 41% 34% 29% 24% 24% 22% 20% 18% 17% 16%
Year 2011 2012 2013 2014 2015 E 2016E 2017E 2018E 2019E 2020E
Cost of Sales 37.88% 38.40% 33.64% 29.93% 31.31% 29.09% 28.47% 27.94% 27.64% 27.31%
R&D 18.81% 23.36% 18.29% 12.79% 9.68% 9.68% 9.68% 9.68% 9.68% 9.68%
General and Admin Costs 36.07% 51.62% 54.65% 47.71% 40.88% 39.01% 38.71% 38.45% 38.32% 38.18%
Other op. Expenses 0.03% 0.29% 0.27% 1.26% 0.36% 0.29% 0.27% 0.25% 0.24% 0.23%
Amort & Dep 8.22% 9.96% 10.02% 10.77% 10.85% 9.36% 15.22% 14.86% 14.14% 13.61%
Year 2015 2016E 2017E 2018E 2019E 2020E
Sales 150 162 182 203 216 231
YoY 35% 8% 12% 11% 7% 7%
Cost of Sales -14 -15 -16 -18 -20 -21
Gross Profit 136 147 165 184 197 210
General and Admnistrative Costs -47 -44 -50 -55 -59 -63
R&D -15 -16 -18 -20 -21 -22
EBITDA 75 87 98 109 117 124
EBITDA Margin 50% 54% 54% 54% 54% 54%
Year 2015 2016E 2017E 2018E 2019E 2020E
sales 535 467 459 453 451 451
YoY -21% -13% -2% -1% -1% 0%
Other income 84 115 111 107 103 98
Cost of sales -201 -175 -172 -170 -169 -169
Gross profit 334 292 286 283 281 282
General and Admnistrative costs -234 -200 -196 -194 -193 -193
R&D -50 -45 -44 -44 -44 -44
Other op exp -3 -2 -2 -2 -2 -2
EBITDA 131 159 155 150 146 141
EBITDA margin 24% 34% 34% 33% 32% 31%
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XVII: THERMIGEN EBITDA Margin 
 
XVIII: POLI GROUP EBITDA Margin 
 
XIX: Revenue by Geographic area 
 
Year 2016E 2017E 2018E 2019E 2020E
Sales 30 53 77 100 111
YoY 0% 78% 44% 30% 11%
Cost of Sales -9 -17 -24 -31 -35
Gross Profit 21 37 53 69 76
General and Admnistrative Costs -12 -21 -31 -40 -44
R&D -3 -5 -7 -10 -11
EBITDA 6 10 15 19 21
EBITDA Margin 19% 19% 19% 19% 19%
Year 2016E 2017E 2018E 2019E 2020E
Sales 85 93 100 108 116
YoY 9% 8% 8% 8%
Cost of Sales -17 -19 -20 -22 -23
Gross Profit 68 74 80 86 93
General and Admnistrative Costs -34 -37 -40 -43 -46
R&D -8 -9 -10 -10 -11
EBITDA 26 28 30 33 35
EBITDA Margin 30% 30% 30% 30% 30%
Geographic area 2011 2012 2013 2014 2015
Spain 50% 41% 38% 30% 32%
Europe excluding Spain 37% 42% 44% 35% 35%
North America 10% 14% 16% 17% 25%
Other 2% 3% 3% 6% 8%
